S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
NASDAQ:VCYT

Veracyte - VCYT Stock Forecast, Price & News

$26.67
-1.22 (-4.37%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$25.80
$27.52
50-Day Range
$22.39
$29.80
52-Week Range
$14.85
$33.23
Volume
551,822 shs
Average Volume
640,734 shs
Market Capitalization
$1.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.86

Veracyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
30.7% Upside
$34.86 Price Target
Short Interest
Healthy
3.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.39mentions of Veracyte in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$5.03 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.61) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

266th out of 1,028 stocks

Medical Laboratories Industry

9th out of 25 stocks

VCYT stock logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
What Makes Veracyte (VCYT) a New Buy Stock
Veracyte Third Quarter 2022 Earnings: Beats Expectations
Veracyte: The FDA Is Stepping In
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Veracyte (NASDAQ: VCYT)
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings
11/09/2021
Today
2/04/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
761
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$34.86
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+30.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-75,560,000.00
Pretax Margin
-15.62%

Debt

Sales & Book Value

Annual Sales
$219.51 million
Book Value
$15.43 per share

Miscellaneous

Free Float
69,672,000
Market Cap
$1.91 billion
Optionable
Optionable
Beta
1.45

Social Links


Key Executives

  • Marc A. StapleyMarc A. Stapley
    Chief Executive Officer & Director
  • Rebecca ChambersRebecca Chambers
    Chief Financial Officer
  • Richard T. Kloos
    Executive Medical Director
  • Robert Brainin
    Chief Business Officer & Executive Vice President
  • Annie McGuire
    Senior Vice President & General Counsel













VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price forecast for 2023?

7 brokerages have issued 1-year price targets for Veracyte's stock. Their VCYT share price forecasts range from $22.00 to $50.00. On average, they anticipate the company's share price to reach $34.86 in the next year. This suggests a possible upside of 30.7% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2023?

Veracyte's stock was trading at $23.73 at the start of the year. Since then, VCYT shares have increased by 12.4% and is now trading at $26.67.
View the best growth stocks for 2023 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.06. The biotechnology company earned $60.37 million during the quarter, compared to analysts' expectations of $54.66 million. Veracyte had a negative net margin of 15.25% and a negative trailing twelve-month return on equity of 4.03%. During the same quarter last year, the firm posted ($0.08) earnings per share.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $288.00 million-$293.00 million, compared to the consensus revenue estimate of $277.79 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.57%), Sumitomo Mitsui Trust Holdings Inc. (4.27%), Fisher Asset Management LLC (2.91%), New York State Common Retirement Fund (1.26%), EFG Asset Management North America Corp. (0.41%) and Essex Investment Management Co. LLC (0.19%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho and Robert S Epstein.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $26.67.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.91 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Veracyte have?

The company employs 761 workers across the globe.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 2/4/2023 by MarketBeat.com Staff